Help your horse breathe easier

Ventipulmin® Syrup

As a basic function of survival, breathing generally requires minimal effort. However, respiratory diseases can cause airways to become constricted —making a simple function far more challenging and complicated than it should be.

When breathing is difficult, it can lead to poor performance and general deterioration of health in horses. Ventipulmin® Syrup delivers relief, allowing horses to breathe easy.

VENTIPULMIN is the only
FDA-approved solution for the management of airway obstruction associated with respiratory disease in horses.1

Important Safety Information: Treatment starting with doses higher than the initial dose is not recommended. Mild sweating, muscle tremors, restlessness, urticaria and tachycardia may be observed in some horses during the first few days of treatment.

Product Resources

Please contribute to the safety and well-being of horses by ensuring responsible administration, dosing and treatment. Prevent the misuse of medications by reading and following label directions.

VENTIPULMIN makes breathing as easy as it should be

  • Acts quickly – reaches lung tissue concentration in less than one hour.2,3
  • Causes smooth muscles in the airway to relax, allowing for bronchodilation. This helps decrease resistance in the respiratory pathway, thus increasing airflow to the lungs.
  • Decreases the thickness of mucus to help improve respiratory airflow.4
  • Palatable, colorless oral syrup for convenient administration and delivery. Respiratory diseases resulting in airway obstruction lead to a constricted bronchial muscle. This makes airflow difficult, leading to labored and difficult breathing.

Common causes of airway obstruction

Several respiratory diseases can lead to airway obstruction in the lower airway of horses. Two of the most common are recurrent airway obstruction (RAO), known as heaves and formerly known as chronic obstructive pulmonary disease (COPD), and inflammatory airway disease (IAD).

RAO is more common in older horses, which are susceptible to recurrent bouts of the disease, whereas IAD can affect all ages and is commonly secondary to viral and bacterial infections.

These two diseases have similar clinical signs; however, the signs for IAD are usually subtle when the horse is at rest.

Management is key

The use of VENTIPULMIN must be combined with proper management for horses with RAO or IAD to successfully and fully improve. These management changes and practices include:

  • Moving the horse outside to pasture when possible;
  • Reducing or eliminating dust exposure; and
  • Using low-dust feed and hay.

Administration:

  • Administer orally twice daily with initial dosage at 0.5 mL/100 lbs of body weight (0.8 mcg/kg). See label for complete dosage schedule.
  • Utilize a treat-to-effect dose schedule for an optimum treatment level.
  • The recommended duration of treatment at the effective dosage is 30 days. If clinical signs return, the 30-day treatment may be repeated, beginning with the initial dosage.

Important Safety Information: 

  • Should not be used in pregnant mares near term.
  • The effect on reproduction in breeding stallions and brood mares has not been determined.
  • Treatment starting with doses higher than the initial dose is not recommended.
  • Because tachycardia may occur, Ventipulmin Syrup should not be used in horses suspected of having cardiovascular impairment.
  • Not for human use. Keep out of reach of children.
  • Please consult package insert for complete product information.

CAUTION: Federal Law restricts this drug to use by or on the order of a licensed veterinarian.

References: 1. Ventipulmin® Syrup (clenbuterol hydrochloride) Freedom of Information Summary, St. Joseph, MO. Boehringer Ingelheim Vetmedica, Inc. 1998. 2. Soma LR,Uboh CE, Guan F, et al. Tissue distribution of clenbuterol in the horse. J Vet Pharmacol Ther 2004;27(2):91–98. 3. Soma LR, Uboh CE, Guan F, et al. Pharmacokinetics anddisposition of clenbuterol in the horse. J Vet Pharmacol Ther 2004;27(2):71–77. 4. Robinson NE. Clenbuterol and the horse, in Proceedings. Annu Conv AAEP 2000;46:229–233.